A Neurofeedback Interface in Poststroke Neuromodulation Using TMS-fNIRS
Stroke is a type of cerebrovascular disease, and the primary characteristic of post-stroke brains is pathological changes in cerebral hemodynamics. Therefore, hemodynamic signals may provide straightforward information for guiding post-stroke neuromodulation therapy. Transcranial magnetic stimulation (TMS), a non-invas
| Condition(s) | Stroke |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Stroke is a type of cerebrovascular disease, and the primary characteristic of post-stroke brains is pathological changes in cerebral hemodynamics. Therefore, hemodynamic signals may provide straightforward information for guiding post-stroke neuromodulation therapy. Transcranial magnetic stimulation (TMS), a non-invasive neurostimulation modality, has been extensively used in post-stroke rehabilitation. However, current TMS-based neuromodulation therapy demonstrates a large treatment response variability due to its open-loop nature. To address this challenge, the research team will develop a novel form of closed-loop neurofeedback interfaces which controls the timing of TMS pulses precisely based on neural biomarkers from functional near-infrared spectroscopy (fNIRS) and test the accuracy |
| Who can participate | Inclusion Criteria: Participants who meet the following criteria will be included: 1. Diagnosed with ischemic subcortical stroke, with stroke onset≥6 months. 2. Age between 18 and 80 years. 3. Residual upper limb functions between levels 2-7 in the FTHUE. 4. Capable of providing informed written consent. 5. Capable of reading and communicating with Chinese. Exclusion Criteria: Patients who meet any of the following criteria will be excluded: 1. any contraindications to TMS (screened by the safety checklist by Rossi). 2. signs of cognitive impairment, with a Montreal cognitive assessment score\<21/22 out of 30. 3. any moderate-to-severe chronic illness, such as uncontrolled hypertension, heart disease or renal failure. Healthy participants should be aged between 18 and 80, with no known his |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | The Hong Kong Polytechnic University |
| Locations | Hong Kong, Hong Kong; Hong Kong, Hong Kong |
| Start date | 2025-08-01 |
| NCT ID | NCT07088107 |
| Official listing | https://clinicaltrials.gov/study/NCT07088107 |